These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30377920)

  • 21. ASO Author Reflections: Proposal of Tumor Size as an Index for Biologic Factor of Resectability Status of Pancreatic Ductal Adenocarcinoma.
    Miyata Y; Kishi Y
    Ann Surg Oncol; 2023 Dec; 30(13):8644-8645. PubMed ID: 37689609
    [No Abstract]   [Full Text] [Related]  

  • 22. ASO Author Reflections: Pancreatic Resection Margins-Chasing Moons.
    Shah MM; Datta J; Merchant NB; Kooby DA
    Ann Surg Oncol; 2022 Mar; 29(3):1551-1552. PubMed ID: 34997421
    [No Abstract]   [Full Text] [Related]  

  • 23. ASO Author Reflections: Low Genetic Testing Utilization Among Patients with Breast, Ovarian, Pancreatic, and Prostate Cancers.
    Clark NM; Flanagan MR
    Ann Surg Oncol; 2023 Mar; 30(3):1327-1328. PubMed ID: 36322272
    [No Abstract]   [Full Text] [Related]  

  • 24. ASO Author Reflections: Relationship Between Sarcopenia, Patient Prognosis, and Tumor-Infiltrating T Cells in Pancreatic Ductal Adenocarcinoma.
    Masuda S; Yamakawa K; Masuda A
    Ann Surg Oncol; 2023 Sep; 30(9):5788-5789. PubMed ID: 37166741
    [No Abstract]   [Full Text] [Related]  

  • 25. ASO Author Reflections: Natural Language Processing Aids in the Detection of Incidental Pancreatic Lesions in Cross-Sectional Imaging.
    Kooragayala K; Lou J; Hong YK
    Ann Surg Oncol; 2022 Dec; 29(13):8520-8521. PubMed ID: 35969301
    [No Abstract]   [Full Text] [Related]  

  • 26. ASO Author Reflections: Regulation of Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma by Vitamin D Supplementation.
    Mukai Y; Eguchi H
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):816-817. PubMed ID: 30324470
    [No Abstract]   [Full Text] [Related]  

  • 27. ASO Author Reflections: Addressing Racial Disparities in Pancreatic Cancer: How Can We Do Better?
    Anteby R; Qadan M
    Ann Surg Oncol; 2023 Apr; 30(4):2482-2483. PubMed ID: 36652023
    [No Abstract]   [Full Text] [Related]  

  • 28. ASO Author Reflections: Racial Disparities in Chemoresponsivity in Localized Pancreatic Cancer: Nature or Nurture?
    Hester CA; Ogobuiro IC; Merchant NB; Datta J
    Ann Surg Oncol; 2023 Mar; 30(3):1495-1497. PubMed ID: 36402894
    [No Abstract]   [Full Text] [Related]  

  • 29. ASO Author Reflections: Disparities in Receipt of Palliative Therapies for Pancreatic Cancer: Did Medicaid Expansion Help?
    Khan H; Crook ED; Heslin MJ; Johnston FM; Fonseca AL
    Ann Surg Oncol; 2023 Jan; 30(1):189-190. PubMed ID: 36245052
    [No Abstract]   [Full Text] [Related]  

  • 30. ASO Author Reflections: Socioeconomic Disparities in Pancreas Cancer Resection and Survival in the Veterans Health Administration.
    Del Valle JP; Gold JS
    Ann Surg Oncol; 2022 May; 29(5):3203-3204. PubMed ID: 35015185
    [No Abstract]   [Full Text] [Related]  

  • 31. ASO Author Reflections: Clinical Significance of Further Subdivision of N Staging in Pancreatic Cancer.
    Asano D; Nara S; Shimada K
    Ann Surg Oncol; 2019 Dec; 26(Suppl 3):766-767. PubMed ID: 31602575
    [No Abstract]   [Full Text] [Related]  

  • 32. ASO Author Reflections: Fluorescent-Guided Surgery to Augment Pancreatic Cancer Surgery.
    Tummers WS; Rosenthal EL; Vahrmeijer AL; Poultsides GA
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):820-821. PubMed ID: 30315384
    [No Abstract]   [Full Text] [Related]  

  • 33. ASO Author Reflections: Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer.
    Andrianello S; Marchegiani G; Salvia R
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):810-811. PubMed ID: 30374921
    [No Abstract]   [Full Text] [Related]  

  • 34. ASO Author Reflections: Contact Between T and N Classifications in Pancreatic Neuroendocrine Neoplasms.
    Xu JZ; Wang WQ; Liu L; Yu XJ
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):814-815. PubMed ID: 30302639
    [No Abstract]   [Full Text] [Related]  

  • 35. ASO Author Reflections: A New Prognostic Factor for Pancreatic Cancer.
    Yoshiya S; Itoh S; Yoshizumi T; Mori M
    Ann Surg Oncol; 2021 Jun; 28(6):3208. PubMed ID: 33230752
    [No Abstract]   [Full Text] [Related]  

  • 36. Linking Disparities to Outcomes in Pancreatic Cancer: Inching Toward Answers.
    Gold JS
    JAMA Surg; 2020 Feb; 155(2):e195082. PubMed ID: 31800009
    [No Abstract]   [Full Text] [Related]  

  • 37. ASO Author Reflections: Serum Elastase 1 Level as a Risk Factor for Postoperative Recurrence in Patients with Well-Differentiated Pancreatic Neuroendocrine Neoplasms.
    Nanno Y; Toyama H
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):800-801. PubMed ID: 30136123
    [No Abstract]   [Full Text] [Related]  

  • 38. ASO Author Reflections: Systemic Inflammatory Markers in Pancreatic Neuroendocrine Tumors.
    Gaitanidis A; Patel D; Kebebew E
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):874-875. PubMed ID: 30353397
    [No Abstract]   [Full Text] [Related]  

  • 39. ASO Author Reflections: Redefining the Ki-67 Index Stratification for Low-Grade Pancreatic Neuroendocrine Tumors.
    Lopez-Aguiar AG; Cardona K
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):826-827. PubMed ID: 30456670
    [No Abstract]   [Full Text] [Related]  

  • 40. ASO Author Reflections: Role of Preoperative Chemotherapy in the Treatment of Pancreatic Neuroendocrine Liver Metastases.
    Tran Cao HS; Vauthey JN
    Ann Surg Oncol; 2018 Dec; 25(Suppl 3):792-793. PubMed ID: 30334195
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.